Adaptive Biotechnologies Corporation is a leader in testing for minimal residual disease in patients with hematologic malignancies, with growth potential and strong near-term drivers. Craig-Hallum rates the stock a "Buy" with a price target of $15.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing